Title :

CD27 is required for protective lytic EBV antigen-specific CD8(+) T-cell expansion

Author(s) :

Deng, Y. [Auteur]
Chatterjee, B. [Auteur]
Zens, K. [Auteur]
Zdimerova, H. [Auteur]
Muller, A. [Auteur]
Schuhmachers, P. [Auteur]
Ligeon, L. A. [Auteur]
Bongiovanni, Antonino [Auteur]
Plateforme BioImaging Center Lille - PLBS [BICeL]
Capaul, R. [Auteur]
Zbinden, A. [Auteur]
Holler, A. [Auteur]
Stauss, H. [Auteur]
Hammerschmidt, W. [Auteur]
Munz, C. [Auteur]

Journal title :

Blood

Abbreviated title :

Blood

Volume number :

137

Pages :

3225–3236

Publication date :

2021

ISSN :

0006-4971

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Primary immunodeficiencies in the costimulatory molecule CD27 and its ligand, CD70, predispose for pathologies of uncontrolled Epstein-Barr virus (EBV) infection in nearly all affected patients. We demonstrate that both ...
Show more >Primary immunodeficiencies in the costimulatory molecule CD27 and its ligand, CD70, predispose for pathologies of uncontrolled Epstein-Barr virus (EBV) infection in nearly all affected patients. We demonstrate that both depletion of CD27+ cells and antibody blocking of CD27 interaction with CD70 cause uncontrolled EBV infection in mice with reconstituted human immune system components. While overall CD8+ T-cell expansion and composition are unaltered after antibody blocking of CD27, only some EBV-specific CD8+ T-cell responses, exemplified by early lytic EBV antigen BMLF1-specific CD8+ T cells, are inhibited in their proliferation and killing of EBV-transformed B cells. This suggests that CD27 is not required for all CD8+ T-cell expansions and cytotoxicity but is required for a subset of CD8+ T-cell responses that protect us from EBV pathology.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Plateformes Lilloises en Biologie et Santé (PLBS) - UAR 2014 - US 41

Research team(s) :

Plateforme BioImaging Center Lille (BICeL)

Submission date :

2023-12-21T07:13:31Z
2024-02-23T21:33:27Z